[ad_1]
A treatment trial was conducted in Japan on 854 people with Alzheimer's disease. Encouraging results suggest a new drug that will slow down the disease.
Japanese laboratory Eisai and its American partner Biogen have just presented the results of a treatment trial at the International Congress of Alzheimer's disease that was held in Chicago a few days ago. This treatment targets the amyloid protein, "the famous protein that is deposited in the brains of patients" explains on France Inter Professor Bruno Dubois, head of the department of cognitive diseases at the Pitié Salpêtrière, who attended this congress
On the same subject
This new treatment was tested on 854 people with a mild form or early of Alzheimer's disease. The results showed that patients who received the highest dose of this drug (a monoclonal antibody called Ban 2401) or 10 mg per kilogram of weight, twice a month intravenously, showed strong reductions of amyloid plaques in their brains
"They had about 93% less beta amyloid compared to people with placebo" is reported on Web MD . These patients also had better results on the ADAS-cog test, a set of 11 tasks to complete that measure memory, language, attention, and other mental deficits.
Dr. Lynn Kramer, Eisai Pharmaceuticals' chief clinical officer, said the company would submit this data to the FDA to discuss next steps. But he did not commit to the date of the phase 3 trial. "We need more data, more time."
[ad_2]
Source link
